Netherlands-based nuclear solutions company NRG Pallas and US medical isotope supplier TAG1 have expanded their partnership to include a multi-year agreement supporting radium-224 supply – a key step in producing lead-212 (Pb-212) and helping targeted alpha therapy for cancer continue to grow worldwide.

The agreement enables the further development and deployment of TAG1’s proprietary Pb-212 generator platform in Europe and unlocks new opportunities for radiopharmaceutical developers and research institutions across the continent, a statement said.